Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

2.

Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup.

Kaplan ID, Cox RS, Bagshaw MA.

J Urol. 1993 Mar;149(3):519-22.

PMID:
7679756
3.

Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.

Zagars GK, Pollack A, von Eschenbach AC.

Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):23-35.

PMID:
7543892
4.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
5.

Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.

Bissonette EA, Fulmer BR, Petroni GR, Moul JW, Theodorescu D.

J Urol. 2001 Oct;166(4):1328-31; discussion 1331-2.

PMID:
11547067
7.

External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.

Akimoto T, Kitamoto Y, Saito J, Harashima K, Nakano T, Ito K, Yamamoto T, Kurokawa K, Yamanaka H, Takahashi M, Mitsuhashi N, Niibe H.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):372-9.

PMID:
15145150
9.

Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI.

Fuchsjäger MH, Pucar D, Zelefsky MJ, Zhang Z, Mo Q, Ben-Porat LS, Shukla-Dave A, Wang L, Reuter VE, Hricak H.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):743-50. doi: 10.1016/j.ijrobp.2009.08.040. Epub 2010 Feb 3.

10.

Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995.

Preston DM, Bauer JJ, Connelly RR, Sawyer T, Halligan J, Leifer ES, McLeod DG, Moul JW.

Urology. 1999 Jan;53(1):131-8.

PMID:
9886602
11.
12.

Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.

Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL.

Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):915-28.

PMID:
14575822
13.
14.

Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.

Soergel TM, Koch MO, Foster RS, Bihrle R, Wahle G, Gardner T, Jung SH.

J Urol. 2001 Dec;166(6):2198-201.

PMID:
11696735
15.

Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer.

Petrovich Z, Lieskovsky G, Langholz B, Jozsef G, Streeter OE Jr, Skinner DG.

Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):600-9.

PMID:
12062603
16.

Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age.

Critz FA, Williams WH, Levinson AK, Benton JB, Schnell FJ, Holladay CT, Shrake PD.

J Urol. 2003 Nov;170(5):1864-7.

PMID:
14532794
17.

Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.

Pollack A, Zagars GK, Kavadi VS.

Cancer. 1994 Jul 15;74(2):670-8.

PMID:
7518341
18.
20.

Supplemental Content

Support Center